AEST.MED.INT.HLD.SP.ADR/3 (3FMA) - Total Liabilities
Based on the latest financial reports, AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has total liabilities worth €484.61 Million EUR (≈ $566.56 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AEST.MED.INT.HLD.SP.ADR/3 cash flow conversion to assess how effectively this company generates cash.
AEST.MED.INT.HLD.SP.ADR/3 - Total Liabilities Trend (2021–2024)
This chart illustrates how AEST.MED.INT.HLD.SP.ADR/3's total liabilities have evolved over time, based on quarterly financial data. See AEST.MED.INT.HLD.SP.ADR/3 book value and equity for net asset value and shareholders' equity analysis.
AEST.MED.INT.HLD.SP.ADR/3 Competitors by Total Liabilities
The table below lists competitors of AEST.MED.INT.HLD.SP.ADR/3 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BIOMIND LABS INC.
F:3XI
|
Germany | €1.62 Million |
|
iTonic Holdings Ltd.
NASDAQ:ITOC
|
USA | $969.83K |
|
NextEnergy Solar Fund Ltd
LSE:NESF
|
UK | GBX201.45 Million |
|
McBride plc
LSE:MCB
|
UK | GBX411.00 Million |
|
Love Group Global Ltd
AU:LVE
|
Australia | AU$1.35 Million |
|
Canada One Mining Corp
V:CONE
|
Canada | CA$1.95 Million |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
UK | GBX1.66 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down AEST.MED.INT.HLD.SP.ADR/3's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AEST.MED.INT.HLD.SP.ADR/3 stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 20.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AEST.MED.INT.HLD.SP.ADR/3's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AEST.MED.INT.HLD.SP.ADR/3 (2021–2024)
The table below shows the annual total liabilities of AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €476.88 Million ≈ $557.52 Million |
-9.52% |
| 2023-12-31 | €527.03 Million ≈ $616.16 Million |
-21.60% |
| 2022-12-31 | €672.25 Million ≈ $785.93 Million |
-11.94% |
| 2021-12-31 | €763.36 Million ≈ $892.45 Million |
-- |
About AEST.MED.INT.HLD.SP.ADR/3
Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and radiofrequency tr… Read more